Literature DB >> 28029753

Performance of the Patient-Reported Outcomes Measurement Information System 29-Item Profile in Rheumatoid Arthritis, Osteoarthritis, Fibromyalgia, and Systemic Lupus Erythematosus.

Patricia Katz1, Sofia Pedro2, Kaleb Michaud3.   

Abstract

OBJECTIVE: The Patient-Reported Outcomes Measurement Information System (PROMIS) was developed to improve measurement of patient-reported outcomes. We examined performance of the 29-item PROMIS Profile (PROMIS-29) in persons with rheumatoid arthritis (RA), osteoarthritis (OA), fibromyalgia (FM), and systemic lupus erythematosus (SLE).
METHODS: Participants in the National Data Bank for Rheumatic Diseases completed the PROMIS-29, which includes 4-item forms for 7 PROMIS domains. Scales were scored and converted to T scores. Distributions of scale scores were examined, convergent and known-groups validity was tested, and differences in scores from online versus paper questionnaires were examined.
RESULTS: Sample sizes were 4,346 for RA, 727 for OA, 241 for FM, and 240 for SLE. Participants were predominantly female, with a mean disease duration ≥20 years, and were ages ∼60 years. Large ceiling effects occurred for some PROMIS-29 scales. Correlations of PROMIS-29 scores with scales measuring similar constructs ranged from high to moderate for RA, OA, and SLE; correlations for FM were markedly lower for some scales. Consistent patterns of worsening PROMIS-29 scores with increasing disease severity or declining health status were observed. Differences in scores obtained by online versus paper questionnaires ranged from 0.3 to 2.2 points.
CONCLUSION: Results provide guarded support for using the PROMIS-29 in these conditions. The PROMIS-29 4-item static forms appear to identify differences among levels of health and to measure constructs similar to those measured by legacy questionnaires. However, large ceiling effects suggest that measurement may be more precise at the "bad" ends of the scales, which may limit responsiveness, and differences by mode of administration appear to exist.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2017        PMID: 28029753     DOI: 10.1002/acr.23183

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  23 in total

1.  Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug.

Authors:  Alyssa Wohlfahrt; Clifton O Bingham; Wendy Marder; Kristine Phillips; Marcy B Bolster; Larry W Moreland; Zhi Zhang; Tuhina Neogi; Yvonne C Lee
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-04       Impact factor: 4.794

2.  Systemic lupus erythematosus: The promise of PROMIS - is it ready for prime time in SLE?

Authors:  Meenakshi Jolly; Patricia Katz
Journal:  Nat Rev Rheumatol       Date:  2017-06-22       Impact factor: 20.543

3.  PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains.

Authors:  David Cella; Seung W Choi; David M Condon; Ben Schalet; Ron D Hays; Nan E Rothrock; Susan Yount; Karon F Cook; Richard C Gershon; Dagmar Amtmann; Darren A DeWalt; Paul A Pilkonis; Arthur A Stone; Kevin Weinfurt; Bryce B Reeve
Journal:  Value Health       Date:  2019-05       Impact factor: 5.725

4.  Measurement invariance and general population reference values of the PROMIS Profile 29 in the UK, France, and Germany.

Authors:  Felix Fischer; Chris Gibbons; Joël Coste; Jose M Valderas; Matthias Rose; Alain Leplège
Journal:  Qual Life Res       Date:  2018-01-19       Impact factor: 4.147

Review 5.  Anxiety and Mood Disorders in Systemic Lupus Erythematosus: Current Insights and Future Directions.

Authors:  Annaliese Tisseverasinghe; Christine Peschken; Carol Hitchon
Journal:  Curr Rheumatol Rep       Date:  2018-11-12       Impact factor: 4.592

6.  Encoding of Self-Referential Pain Catastrophizing in the Posterior Cingulate Cortex in Fibromyalgia.

Authors:  Jeungchan Lee; Ekaterina Protsenko; Asimina Lazaridou; Olivia Franceschelli; Dan-Mikael Ellingsen; Ishtiaq Mawla; Kylie Isenburg; Michael P Berry; Laura Galenkamp; Marco L Loggia; Ajay D Wasan; Robert R Edwards; Vitaly Napadow
Journal:  Arthritis Rheumatol       Date:  2018-06-22       Impact factor: 10.995

7.  Use of PROMIS-29® in US Veterans: Diagnostic Concordance and Domain Comparisons with the General Population.

Authors:  Sherri L LaVela; Bella Etingen; Scott Miskevics; David Cella
Journal:  J Gen Intern Med       Date:  2019-05-29       Impact factor: 5.128

8.  PROMIS®-29 v2.0 profile physical and mental health summary scores.

Authors:  Ron D Hays; Karen L Spritzer; Benjamin D Schalet; David Cella
Journal:  Qual Life Res       Date:  2018-03-22       Impact factor: 4.147

9.  A randomized, controlled study to evaluate the efficacy of intra-articular, autologous adipose tissue injections for the treatment of mild-to-moderate knee osteoarthritis compared to hyaluronic acid: a study protocol.

Authors:  Ian A Jones; Melissa Wilson; Ryan Togashi; Bo Han; Austin K Mircheff; C Thomas Vangsness
Journal:  BMC Musculoskelet Disord       Date:  2018-10-24       Impact factor: 2.362

10.  Evaluating the PROMIS-29 v2.0 for use among older adults with multiple chronic conditions.

Authors:  Adam J Rose; Elizabeth Bayliss; Wenjing Huang; Lesley Baseman; Emily Butcher; Rosa-Elena García; Maria Orlando Edelen
Journal:  Qual Life Res       Date:  2018-08-07       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.